The US FTC challenges a merger using a monopolization theory to allege that the merger would eliminate nascent competition in the therapeutic adrenocorticotropic hormones (Questcor Pharmaceuticals / Mallinckrodt)

Heltzer, Gregory E.

Article précédent The US FTC reviews thresholds pre-merger notification under the Hard-Scott-Rodino Act Article suivant The Indian Competition Authority fines merging parties for failure to disclose the global acquisition of a healthcare antisepsis business (Schulke / ASP Division of Ethicon)

18 Jan 2017

The US FTC challenges a merger using a monopolization theory to allege that the merger would eliminate nascent competition in the therapeutic adrenocorticotropic hormones (Questcor Pharmaceuticals / Mallinckrodt)

KEYWORDS

Reference

US FTC, Questcor Pharmaceuticals / Mallinckrodt, Press Release, 18 January 2017

The Federal Trade Commission (FTC) challenged a consummated transaction using a monopolization theory to allege that the acquisition would eliminate “nascent” competition for therapeutic adrenocorticotropic hormones (ACTH) in the United States. WHAT HAPPENED: Questcor Pharmaceuticals, Inc.’s (Questcor) H.P. Acthar Gel (Acthar) is the only ACTH product sold in the US, is the standard of care for

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

Version PDF

Auteur

Gregory E. Heltzer
McDermott Will & Emery (Washington)

États-Unis 34 contributions 5390 visites

Citation

Gregory E. Heltzer, The US FTC challenges a merger using a monopolization theory to allege that the merger would eliminate nascent competition in the therapeutic adrenocorticotropic hormones (Questcor Pharmaceuticals / Mallinckrodt), 18 janvier 2017, e-Competitions January 2017, Art. N° 93369

Visites 112